J&J to Acquire Actelion for $30 billion
The companies will split Actellion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.
On Jan. 26, 2017, Johnson & Johnson (J&J) announced plans to acquire Actelion for $30 billion. In a press release, J&J said it would acquire all outstanding shares of Actelion for $280 per share. J&J will retain Actelion’s presence in Switzerland and the companies will split Actelion’s drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company, R&D NewCo.
The shares of R&D NewCo, which will be listed on the SIX Swiss Exchange (SIX), will be distributed to Actelion’s shareholders as a stock dividend upon closing of the tender. Johnson & Johnson will initially hold 16% of the shares of R&D NewCo and have rights to an additional 16% of R&D NewCo equity through a convertible note. The arrangements will result in R&D NewCo launching with cash of CHF 1 billion (approximately $1 billion) to be made available at the closing of the transactions.
J&J will also receive an option on ACT-132577, R&D NewCo product being developed for resistant hypertension currently in Phase II clinical development. The new company will be led by Actelion’s current scientific team with Jean-Paul Clozel, MD, CEO and founding member of Actelion, as CEO. Jean Pierre Garnier, Chairman of the Board of Actelion, will be Chairman of the Board of R&D NewCo.
Source: J&J
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
